As Meta approaches earnings, the company faces its biggest strategic test yet. The collision between massive AI spending and Reality Labs’ continued losses could define the company’s future trajectory.
Chegg’s market value has plummeted $14.5 billion since 2021 as students abandon paid services for free AI tools. With 45% layoffs and failed AI initiatives, can this education company survive the ChatGPT revolution?
General Motors is eliminating 1,750 positions in response to slowing EV demand and expiring federal tax credits. The cuts reflect a broader industry recalibration as automakers face changing regulatory and market conditions.
A startup founded by former Google quantum researchers has unveiled working hardware that could disrupt the AI data center boom. Extropic’s thermodynamic chips use probabilistic bits to achieve unprecedented energy efficiency for complex simulations.
Sam Altman discloses OpenAI has committed to spend approximately $1.4 trillion on AI infrastructure development. The massive investment equates to roughly 30GW of data center capacity as the company navigates regulatory challenges.
Microsoft Azure is experiencing a significant global outage affecting Microsoft 365, Xbox, Minecraft, and major business websites. The outage comes just hours before Microsoft’s quarterly earnings announcement and follows recent AWS disruptions.
General Motors is cutting thousands of EV and battery factory workers and idling production facilities until 2026. The move represents a dramatic scaling back of the automaker’s electric vehicle ambitions amid changing market conditions.
A revolutionary antivenom using lab-synthesized nanobodies from alpacas and llamas could transform snakebite treatment. The technology promises to be safer, cheaper, and more effective than current horse-derived antivenoms that fail many of the world’s poorest communities.
Researchers have discovered how to design molecular “glues” and “bumpers” that precisely control GPCR signaling pathways. This breakthrough could overcome decades of failed promises in biased drug development and create more targeted therapeutics.
The Federal Reserve makes a dual policy shift, cutting rates for the second consecutive meeting while announcing an end to quantitative tightening. This coordinated move reflects growing concerns about employment risks and market stability.
